Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson’s Disease to Recombinant DNA Advisory Committee

June 8, 2011 By Bio-Medicine.Org

FORT LEE, N.J., June 8, 2011 /PRNewswire/ — Neurologix, Inc.
(OTCBB: NRGX) announced today several new results from the
Company’s successful Phase 2 clinical trial for its novel,
investigational gene therapy NLX-P101 for the treatment of
Parkinson’s disease (PD) as part of a comprehensive presentation of
study findings to the National Institutes of Health (NIH)
Recombinant DNA Advisory Committee (RAC). Recently completed
analysis of new data showed patients treated with NLX-P101 had
significantly increased “ON” times, or periods in which the
symptoms of PD are best controlled, compared to sham subjects over
the course of 12 months following treatment (p<0.05; ANOVA).
Significant reductions in complications due to medical therapy were
also seen following treatment with NLX-P101. These new findings,
which demonstrate patients treated with NLX-P101 maintained
statistically significant, positive, long-term improvements at 12
months, were included in today’s presentation of results from the
landmark Phase 2 trial by Matthew J. During, M.D., D.Sc., one of
the scientific co-founders of Neurologix.

Patients with moderate to advanced PD often suffer from reduced
effectiveness of medication, including less time spent each day in
the better or “ON” state. The new findings presented today of the
NLX-P101 Phase 2 study demonstrated that treatment with the novel
gene therapy resulted in an average daily increase of 2.5 hours of
“ON” time at 3 months (p<0.01 relative to baseline; t-test) and
this increase was sustained at 2.1 hours of greater “ON” time at 12
months (p<0.01 relative to baseline; t-test). There was no
significant increase in “ON” time in sham patients at any time
point.  

There was also a significant reduction in complications of
medication in the NLX-P101 group at 6 and 12 months following
treatment (p<0.01 and p<0.05, respectively; t-test) as
measured by Part 4 of the Unified Parkinson’s Disease Rating Scale
(UPDRS), with no s

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech